Actively Recruiting
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Led by Mayo Clinic · Updated on 2026-05-05
332
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the overall burden of tau protein in the brains of patients with Progressive Supranuclear Palsy (PSP). This study aims to better understand how tau accumulates in PSP, which is a progressive brain disorder. The research is led by the Mayo Clinic and involves patients aged 35 and older who show symptoms of PSP. Participants will undergo a Tau PET scan using a tracer called F-18 AV 1451 to image tau protein in the brain. All participants receive this scan as part of the study. The study includes a primary outcome measure focusing on the amount of tau protein detected over a 5-year period, with secondary measures tracking changes in tau burden at baseline and after one year. During the study, participants will be assessed through these imaging scans to observe tau accumulation and progression over time. Researchers will monitor participants for up to five years to evaluate tau protein levels and how they change. The study includes safety considerations such as excluding those with other neurological diseases or conditions that could affect brain imaging results.
CONDITIONS
Brief Title
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be over 35 years of age and present with gradual progression of PSP-related symptoms
- Must have an informant or study partner that can provide independent information of functioning
- Must meet criteria for possible or probable Progressive Supranuclear Palsy, including specific eye movement and postural instability features within the first year of disease onset
You will not qualify if you...
- Diagnosis of other neurodegenerative diseases such as corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy, or Parkinson's disease
- Presence of concurrent illnesses that could explain symptoms, including traumatic brain injury, encephalitis, strokes, or developmental syndromes
- Women who are pregnant, postpartum, or breastfeeding
- Genetic conditions increasing cancer risk such as Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, or Down's syndrome
- Contraindications for MRI, severe claustrophobia, or brain conditions that may affect imaging results
- Medically unstable individuals or those on medications affecting brain structure or metabolism
- Lack of an informant or refusal to consent to research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Baseline and 1 year
Participants undergo a Tau PET scan to measure the amount of Tau protein in the brain.
2 visits (in-person)
Duration - Up to 5 years
Participants are observed to assess changes in Tau protein levels over time.
Periodic assessments
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
S
Sarah M Boland, CCRP
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here